CD4 and neoplasm: PRMT2 can induce the polarization of tumor-associated macrophages (TAMs) towards the M2 phenotype (tumor-promoting, immunosuppressive) and inhibit the function of CD4+ and CD8+ T cells, leading to their exhaustion, thereby synergistically driving tumor progression and immune escape [52].